Your browser doesn't support javascript.
loading
Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats.
Wyde, P R; Moore, D K; Hepburn, T; Silverman, C L; Porter, T G; Gross, M; Taylor, G; Demuth, S G; Dillon, S B.
Afiliación
  • Wyde PR; Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Texas 77030, USA.
Pediatr Res ; 38(4): 543-50, 1995 Oct.
Article en En | MEDLINE | ID: mdl-8559607
Reshaped human MAb RSHZ19, which is specific for the surface fusion protein of respiratory syncytial virus (RSV) is in clinical development for the prevention and treatment of RSV-induced disease in human infants. The current studies profile lung virus clearance and evaluate lung histopathology in MAb-treated, RSV-infected cotton rats, a well characterized model of RSV infection. The highest dose of this MAb (10 mg/kg) administered parenterally 24 h before infection decreased subgroup A or B RSV lung titers to below detectable levels (> or = 2.3 log10 reduction), and significantly reduced lung virus titers (> or = 2.0 log10 reduction) when administered 96 h postinfection. Prophylactic administration of 10 mg/kg RSHZ19 was significantly more protective than 1000 mg/kg conventional human immune serum globulin (HSIg), and protective serum-neutralizing titers in MAb-treated animals (1:32, which correlated with approximately 40 micrograms/ml determined by anti-idiotype ELISA) were significantly lower than those reported previously for HSIg or for convalescent human serum (1:200-1:400). MAb concentration in lung lavages was determined by ELISA to be approximately 1% of the serum MAb concentration, but was not detectable by neutralization assay. The degree of lung histopathology in MAb-treated cotton rats was proportional to lung virus titer, and inversely proportional to the RSHZ19 dose administered. There was no evidence of exacerbated disease in the lungs of MAb-treated animals. These studies thus support the potential clinical utility of RSHZ19 MAb in the prevention and treatment of RSV-induced disease in humans.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Virus Sincitiales Respiratorios / Infecciones por Virus Sincitial Respiratorio / Anticuerpos Monoclonales Tipo de estudio: Diagnostic_studies / Evaluation_studies Límite: Animals / Humans / Infant Idioma: En Revista: Pediatr Res Año: 1995 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Virus Sincitiales Respiratorios / Infecciones por Virus Sincitial Respiratorio / Anticuerpos Monoclonales Tipo de estudio: Diagnostic_studies / Evaluation_studies Límite: Animals / Humans / Infant Idioma: En Revista: Pediatr Res Año: 1995 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos